New all-island research from Queen’s University Belfast and UCD highlights the health and economic impact of the Good Friday Agreement on cancer across the island of Ireland in the last 25 years.

The work, involving researchers from Ireland, Northern Ireland, the UK and the U.S. has been published today in the Journal of Cancer Policy, the number one cancer policy journal globally.

The study highlights the impact of the Ireland - Northern Ireland – U.S. National Cancer Institute Cancer Consortium. This unique partnership, established in 1999, between the governments of Ireland, Northern Ireland and the U.S., was a direct result of the Good Friday Agreement. It shows how the Consortium acted as a catalyst, enhancing cancer research quantity and quality both between researchers in Northern Ireland and Ireland and with premier institutions in the U.S., leading to improved cancer outcomes on the island of Ireland.

The research highlighted a 550% increase in the quality of joint cancer research on the island, an economic dividend of that enhanced research leading to an increase in university spin-out activity and an improvement in cancer outcomes on the island of Ireland.  

Lead Author Professor Mark Lawler, QUB and co-lead of the All-Island Cancer Research Institute (AICRI), recently presented the research at the Science Summit of the UN General Assembly. He said: “This research highlights the significant cancer legacy that the peace process and the Good Friday Agreement have delivered for people from all parts of this island. This unique partnership has been truly transformative, saving thousands of lives and driving significant research and innovation that will have both health and economic impact for this island.” 

Professor William Gallagher, Professor of Cancer Biology at UCD School of Biomolecular and Biomedical Science, Co-Lead of AICRI and co-author on the study said: “Working together in a shared partnership, AICRI and the Ireland-Northern Ireland US-NCI Consortium can deliver high quality research that directly translates into patient benefit across the island of Ireland.” 

U.S. Special Envoy for Northern Ireland Economic Affairs Joseph Kennedy III, leading a US business delegation to Northern Ireland said: “I highlighted this work at the BIO International Convention in Boston earlier this year. It demonstrates how a transatlantic partnership, fostered through the Good Friday Agreement, can drive a research and innovation agenda that delivers tangible benefits for people and societies on the island of Ireland. The potential health and economic benefits for Northern Ireland are significant, aligning with initiatives such as the Belfast Region Growth Deals.”

U.S. Special Envoy for Northern Ireland Economic Affairs Joseph Kennedy III, leading a US business delegation to Northern Ireland said: “I highlighted this work at the BIO International Convention in Boston earlier this year. It demonstrates how a transatlantic partnership, fostered through the Good Friday Agreement, can drive a research and innovation agenda that delivers tangible benefits for people and societies on the island of Ireland. The potential health and economic benefits for Northern Ireland are significant, aligning with initiatives such as the Belfast Region Growth Deals.”

Co-author in the study and patient advocate Debbie Keatley added: “This work shows how much the cancer research landscape has changed in the last twenty-five years. The work of patients and advocates no longer exists on the margins. They are taking their rightful place as equal partners in this endeavour; in the rooms and at the tables where decisions are made about research and treatments that affect them. “Groups like Patient Voice in Cancer Research and Northern Ireland Cancer Research Consumer Forum are working together with researchers, all focused on a single aim - to improve cancer outcomes for people across Ireland and beyond. The learning is clear; when you truly want to make progress, make space at the table for patients.”

Dr Satish Gopal, Director of the Centre for Global Health at the NCI and senior author on the study, said: “We are delighted to have been a partner in this work over the last 25 years. This research exemplifies how by collaborating together across borders, we can achieve transformative change. Cancer is a global challenge and initiatives such as this point the way forward.”

Professor Karen McCloskey, Deputy Director of the Patrick G. Johnston Centre for Cancer Research at Queen’s and co-author on the research, said: “The partnership is all about people: patients, students, scientists, clinicians, and policy makers. Together, we continue to train the leading scientists and clinicians of tomorrow. The job is not done. As my colleague Professor Lawler frequently says “Cancer knows no borders” - so we continue to forge new global partnerships, ignoring any borders. As a global team, our collective expertise, complementary skills and shared ambition achieve much more than we could imagine without this partnership.” 

Professor Lawler added: “To paraphrase our dear departed friend Paddy Johnston, – “Dream no little dreams, for they stir not the hearts of men nor women”. We need to be bold; we need to be ambitious and, most of all, we need to work together to address one of the greatest challenges in human health. Cancer knows no borders – this transatlantic partnership is direct evidence of this and continues to give and give.”

Read the full press release from Queens University Belfast here.

Pictured: Prof Mark Lawler and Prof William Gallagher; Prof Mark Lawler with U.S. Special Envoy for Northern Ireland Economic Affairs Joseph Kennedy III and Dr Karen McCloskey.